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Background: Community engagement (CE) is increasingly promoted for biomedical research conducted in
resource poor settings for both intrinsic and instrumental purposes. Given the potential importance of CE, but also
complexities and possibilities of unexpected negative outcomes, there is need for more documentation of CE
processes in practice. We share experiences of formal CE for a paediatric randomized controlled malaria vaccine trial
conducted in three sites within Kilifi County, Kenya.
Methods: Social scientists independent of the trial held in-depth individual interviews with trial researchers (n = 5),
community leaders (n = 8) and parents (15 with enrolled children and 4 without); and group discussions with
fieldworkers (n = 6) and facility staff (n = 2). We conducted a survey of participating households (n = 200) and
observed over 150 CE activities.
Results: The overall CE plan was similar across the three study sites. The majority of respondents felt that CE
activities helped to clear pre-existing concerns and misconceptions, and increase familiarity with and trust in trial
staff. Challenges included: some community leaders attempting to exert pressure on people to enrol; local wording
in information sheets and consent forms feeding into serious anxieties about the trial; and concerns about reduced
CE over time. Negative effects of these challenges were mitigated through changes to on-going CE activities,
and final information sharing and consent being conducted individually by trained clinical staff. One year after
enrolment, 31% (n = 62) of participants’ parents reported malaria prevention as the main aim of the activities their
children were involved in, and 93% wanted their children to remain involved.
Conclusion: The trial teams’ goals for CE were relatively clear from the outset. Other actors’ hopes and expectations
(like higher allowances and future employment) were not openly discussed, but emerged over the course of
engagements. Encouraging open discussion of all actors’ intentions and goals from the outset takes time, risks
raising expectations that cannot be met, and is complex. However, doing so in future similar trials may allow
successes here to be built upon, and some challenges to be minimized or avoided.
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Community engagement (CE) is increasingly promoted
for biomedical research conducted in resource poor set-
tings [1], for both intrinsic reasons (for example to show
respect and trustworthiness) and instrumental reasons
such as strengthening science through improving accept-
ability and interest in research, and strengthening ethical
practice through improving consent processes [2,3].
While few would argue with these goals of CE, the
complexity and the contested nature of all key elements
of CE are becoming increasingly recognised [4,5]. With
regards to ‘community’, it is unclear how this should be
defined, given that individuals are always members of
multiple communities, with membership shifting over
time and space. In non-participatory health research,
communities are often defined in relation to the nature
of the research activity (for example does it involve a
particular geographical area or illness group?) and the
location of the research institution (for example is it
based in a rural or urban setting, and is the population
relatively mobile or stable over time?) [6,7]. Empirical
studies have also suggested that for health research, the
Ministry of Health (MoH) and other key health pro-
viders are often important key communities to include
[8]. Even where there is clarity on which key communi-
ties to engage with, how representatives of those com-
munities should be selected, and how researchers should
work with those communities to ensure that their con-
tribution is recognised but their independence from re-
searchers is maintained, is far from straightforward [6].
In terms of ‘engagement’, definitions can vary from many
different formal and informal communication activities,
through to more specific interventions such as deliberate
employment of local community members by research
organisations as field staff, and provision of services such
as health care [9]. In an international meeting on con-
sent and CE, participants reached a consensus to define
CE primarily as communication activities, with the
provision of health and other services and care consid-
ered as crucial activities (often informed by CE) but con-
ceptually separate from CE. It was agreed that the
provision of health care and other services could instead
be considered as part of research design (including ancil-
lary care) and benefit sharing. Even where CE is consid-
ered as primarily about communication, engagement
activities can cover a wide range of interactions includ-
ing those aimed at consulting with community members
about what should be done in studies, through those
aimed at sensitising community members about research
or specific studies, to activities aimed at ensuring com-
munities receive feedback of individual test results or
overall study findings [8,10]. These activities are often
part of formally organised communication strategies and
activities of research institutions. However research staff,collaborators and colleagues in Ministries of Health also
have informal interactions about research and re-
searchers in the multiple communities that they are
members of. This web of informal communication and
interaction can play a key role in community members’
perceptions of and relationships with individual research
staff and the institutions they belong to [9,11-14].
Formal engagement activities can take place at any stage
of research, although it is recognised that the amount of
engagement often reduces over time as studies progress,
with some arguing that feedback of study findings at
the end of research is often given inadequate atten-
tion [15]. Engagement can be through structures that
exist independently of research such as chiefs, elders,
and women’s groups, or through structures specifically
established by research organisations such as various
forms of Community Advisory Boards or Groups (CABs
or CAGs) [6]. The importance of ensuring that traditional
decision-making structures such as chiefs, elders and
health managers are engaged with has been highlighted in
empirical studies [1,16,17]. However, also highlighted in
the literature has been the importance of ensuring repre-
sentation of those with less authoritative positions in com-
munities; of ensuring that both ‘typical’ members of
communities and the most vulnerable and often least vis-
ible and vocal groups are heard [9]. In practice, communi-
cation activities often involves a variety of different
structures and groups, with activities of varying sizes po-
tentially being conducted in many different settings, in-
cluding homes, communities, health facilities and research
centres. Where meetings are held and how large and regu-
lar they are, has implications for who is willing and able to
attend, how much information can realistically be covered
in what depth, how much interaction and discussion is
possible, and how free participants feel to raise their views
and concerns [6,18].
A fundamental challenge in practice for formal CE
strategies is that researchers’ goals of CE are often im-
plied rather than clearly articulated [5,8]. This is an im-
portant challenge because many CE initiatives have
diverse goals, which may be in tension with each other,
and because all CE has the potential to have a negative
impact, at the very least through taking up people’s time,
but also through unintended perverse outcomes such as
making some individuals feel obliged to take part in re-
search through peer pressure, or raising expectations
that cannot be met [1,6,16,19,20]. Another reason that
greater clarity in goals is important is that there is
clearly a limit to what ethical issues CE itself can resolve
in research, including those related to historical and
background injustices and inequities, and unfair distri-
bution of risks and benefits in research [5]. Recognition
of the limits of CE, as CE is defined here, is important in
highlighting the need for broadening the scope of CE
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undertaking these; for incorporating other initiatives and
thinking to strengthen ethical research practice. Beyond
clarity in CE goals, other fundamental issues in practice
in CE include taking into consideration who drives the
CE agenda, how power relations feature in community-
researcher interactions, and how research findings are
shared with policy-makers and implementers in a position
to influence policy and practice in the longer term [4].
Relatively few recent studies have examined CE pro-
cesses in practice. Given the potential importance of CE,
but also the complexity and potential for perverse out-
comes such as those listed above, there is a recognised
need for more documentation of micro-processes as they
unfold on the ground. Such research needs to go far be-
yond documenting simple consent rates: participation in
research is only one possible goal of CE, and achieving
this goal can compete with other goals such as strength-
ening understanding of the trial and its’ implications for
individual participants. Moreover, participation rates are
also influenced by many factors beyond CE [8].
In this paper we share on-going experiences of formal
CE for a paediatric randomized controlled malaria vac-
cine trial conducted in three different sites in one geo-
graphical area of Kilifi County on the Kenyan Coast. The
trial was conducted in three local health facilities, and
involved healthy infants and children. Although the trial
is on-going, we draw on data collected between 2009
and 2011 from a large mixed method study running con-
currently with the trial. Following an overview of the
study setting, trial, and qualitative study methods, we de-
scribe the processes followed in CE, how these changed
over time, the goals of involving different community ac-
tors in CE processes from the trial team’s perspective,
and trial staff and community members’ perceptions of
the successes and challenges of the approaches followed.
We then discuss the levels of understanding of the trial
among participants’ parents, measured one year after
consenting. Finally, we draw on our data and the wider
literature to show that the complexity of CE in our set-
ting was exacerbated by the very different realities, goals
and interests that the various actors brought to the ac-
tivities and interactions, including diverse and multi-
layered practices of power. The implications for future
CE activities and how to evaluate these are discussed.
Study context
Study setting and CE activities
The paediatric randomized controlled malaria vaccine
trial began in 2009 and is on-going (ClinicalTrials.gov;
NCT00866619); see also, [21]. It is being conducted by
the Kenya Medical Research Institute/Wellcome Trust
Research Programme (KEMRI/WTRP, or KWTRP) in
several administrative divisions within Kilifi County, onthe Kenyan Coast. Kilifi County has low literacy levels,
high poverty rates, and farming is the main occupation
[22]. KWTRP has a long history of multi-disciplinary re-
search in Kilifi County, including empirical studies on
consent and CE.
All studies conducted by KWTRP in Kilifi County are
supported by the Community Liaison Group (CLG); a
group of six facilitators, four senior fieldworkers (FWs)
and a Community Liaison Manager, responsible for en-
suring that mutual understanding is built, and that there
are strong, honest and supportive relations between staff
and local residents [23]. The CLG develop and imple-
ment annual plans for CE activities in the programme,
supported by three senior researchers with an interest in
research ethics. CLG activities can be broadly divided
into programme-wide CE, and project-specific engage-
ment activities. Programme-wide CE activities focus on
the 260,000 people living within the Kilifi Health and
Demographic Surveillance System (KDHSS) area [22],
and include: information sharing on what research is
and how participants’ rights are protected in research,
and on new studies; consultation with community repre-
sentatives (chiefs, leaders, and typical community mem-
bers) on planned or on-going research or research policy;
and feedback of research findings. Programme guidelines
have been developed to support study teams to design
appropriate CE plans for each study. To support study-
specific CE plans, CLG members and trial representatives
sit on a Community Advisory for Study Teams (CAST) set
up for each study that requires CE. Through this mechan-
ism, CLG members advise on activities with the aim of
ensuring that issues raised through interactions with com-
munity members are discussed with key stakeholders at
the Programme and externally where appropriate.
The CE discussed in this paper was for a trial being con-
ducted outside the KHDSS, in two locations bordering the
KHDSS but further inland, involving three rural health fa-
cilities referred to here as sites A, B and C respectively
(see also Figure 1). The locations where the trial is being
conducted had very little direct involvement with the re-
search organisation prior to this trial, and there were pre-
viously no programme-wide CE activities being regularly
conducted. A CAST group was therefore set up for this
trial, including CLG members (facilitators and a senior
fieldworker) and trial team staff (a senior trial researcher
and manager) to advise on the design and implementation
of CE activities. The CE plan developed by the CAST
group drew upon previous findings and experiences of a
similar trial conducted in other parts of Kilifi District [8].
The overall aims outlined in the strategy were to:
 Consult with community representatives and other
key stakeholders on how to work in facilities and
communities, and who to engage with and how;
Figure 1 Map of trial sites.
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new sites;
 Gather community leaders’ opinions of the study;
 Build trust with key community leaders and
representatives; and
 Provide a forum for discussing and addressing issues
arising from participants and community
representatives.
Trial design
The trial is described in detail elsewhere [21]. In summary,
904 children aged 5 to 17 months and 6 to 12 weeks at en-
rolment were recruited from villages surrounding three
rural local health facilities in Vitengeni and Ganze district.
The trial aimed to document the vaccines’ safety, im-
munogenicity and efficacy against febrile malaria in
children through a double-blind randomized controlled
design; the primary outcome was clinical malaria episodes.
For participating children the trial involved: an initial
health check; randomization into one of three arms, that
is malaria vaccine only, malaria vaccine and comparator,
or comparator vaccine only; four vaccination visits to the
health facility; and monthly home visits by a FW for four
years. The trial vaccines were co-administered with rou-
tine childhood vaccines and given at months 1, 2, 3 and a
booster dose administered at month 18. Participants’ par-
ents were encouraged to report any health concerns to the
study team as soon as possible. Study benefits for partici-
pants included free treatment for any illnesses, payment oftransport costs for any visits to the health facility, and
an ability to communicate with locally resident trial staff
fieldworkers; 24 hours a day. FWs were in turn able to
phone medically qualified staff to facilitate referrals,
where necessary. Refreshments were provided during
study-organised health facility visits.
Methods
Study design
The data from this paper were collected by social scien-
tists with strong links with, but who were not part of,
the KWTRP Community Liaison Group, or the trial
team. The study design was a mixed methodology descrip-
tive approach combining individual and group in-depth
interviews, surveys, observations and document reviews.
In addition to each method making a unique contribution
to understanding complex realities of CE for this trial,
using multiple methods allowed us to continue to evolve
our research tools and understanding. For example obser-
vations fed into interview tools and vice versa, and the
survey questions drew upon in-depth interview informa-
tion and tested commonness of points made. In this paper
we present data collected between 2009 and 2011; a
period of intense activity for the trial.
Non-participant and participant observation
We conducted both participant and non-participant obser-
vation. We participated in the trial’s CE CAST meetings,
and observed consent and CE activities in the community
Table 2 Characteristics of survey interviewees
(Household survey)
Site A
n = 67 (%)
Site B
n = 33 (%)
Site C
n = 100 (%)
Total
n = 200 (%)
Sex
Male 6 (9.0) 3 (9.1) 5 (5.0) 14 (7.0)
Female 61 (91.0) 30 (90.9) 95 (95.0) 186 (93.0)
Age, years
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in villages (n = 42 meetings), accompanied FWs and
community facilitators on visits to potential participants’
homes (n = 87 home visits), and attended 31 facility-based
information-giving sessions. Semi-structured observation
tools captured verbal and non-verbal information, includ-
ing who attended and participated in activities, what infor-
mation was covered, what questions were asked, and how
questions and concerns were handled.
In-depth interviews (individuals and groups)
Interviews aimed at exploring people’s experiences and
perceptions of the trial’s informed consent process and
CE activities across the three trial sites. Interviewees
were purposively selected to maximise diversity of ex-
perience, taking into account for example, role in the
trial, enrolment status, gender and location. Individual
in-depth interviews (IDIs) were held with (see Table 1):
trial researchers (n = 5); community leaders (n = 8) in-
cluding chiefs, village elders, health facility committee
representatives and community health workers (CHWs);
and parents (15 with enrolled children and 4 without).
Group discussions were also held with health facility
staff (n = 2 groups; 5 staff in total) and trial FWs from
the three sites (n = 6 groups; 20 FWs in total with most
interviewed twice). Interviews covered the following topics:
how communities were involved and informed about the
trial, and what influenced their decision-making about
joining or refusing; their understanding, views and experi-
ences of the trial and of CE activities; and their own and
others’ ability to communicate concerns to the trial team.
We also sought recommendations for future similar trials.
Semi-structured household survey
A household survey, administered one year after recruitment,








IDIs with parents of children
enrolled in the trial
15 15
IDIs with parents of children
not enrolled in the trial
4 4
Household semi-structured
survey with parents of children
in the trial
200 200
Trial staff Trial staff IDIs 5 5
Fieldworkers FGDs 6 20 fieldworkers
Health workers
and leaders
Health facility staff group
interviews
2 5
Community leaders IDIs 8 8
FGD, focus group discussion; IDIs, in-depth interviews.among many parents/guardians of children enrolled in the
trial, to have some sense of commonness of findings
across participants. We were particularly interested in ex-
ploring whether levels of understanding among parents/
guardians of trial participant differed by site, and particu-
larly sites A and C (the start and end) on the basis of ini-
tial qualitative data. Survey respondents were randomly
selected from the trial database of all participants, propor-
tional to the total number of trial participants per site.
In total, 200 participants were surveyed; 67 from site A,
33 from site B and 100 from site C. Of the 200 sampled
households for this study, only one had to be replaced
since we could not find them after three consecutive visits.
Demographic characteristics of survey respondents are
highlighted in Table 2.
Document reviews
To supplement the above activities, we reviewed the
KWTRP CE guidelines, the trial’s CE plan and minutes
from all CE-related meetings.
Data management and analysis
Interviews, observations and the household survey were
conducted primarily by the first and second authors (VA
and DK) together with four trained senior (non-trial)
FWs who speak the local dialect. Community interviews16 to 24 15 (22.4) 7 (21.2) 24 (24.0) 46 (23.0)
25 to 44 50 (74.6) 25 (75.8) 72 (72.0) 147 (73.5)
45 and above 2 (3.0) 1 (3.0) 4 (4.0) 7 (3.5)
Religion
Christian 36 (53.7) 19 (57.6) 46 (46.0) 101 (50.5)
Muslim 6 (9.0) 0 19 (19.0) 25 (12.5)
None/traditional 25 (37.3) 14 (42.4) 35 (35.0) 74 (37.0)
Highest level of
education
None 23 (34.3) 9 (27.3) 39 (39.0) 71 (35.5)
Some primary
education
34 (50.8) 23 (69.7) 54 (54.0) 111 (55.5)
Some secondary
education
5 (7.5) 1 (3.0) 3 (3.0) 9 (4.5)
Adult education 4 (6.0) 0 3 (3.0) 7 (3.5)
Tertiary and
above
1 (1.5) 0 1 (1.0) 2 (1.0)
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by the interviewees.
Qualitative interviews were audio taped, transcribed
and translated into English (where necessary), and coded
and analysed using a framework approach [24] in NVivo
8 (QSR International, Melbourne, Australia). VA and
SM developed the initial coding framework based on the
study objectives and a review of a sub-set of the data, with
initial themes including: CE goals (at the outset of the
trial, over time, and at the end of the trial); understanding
of and perceptions of the KWTRP, the trial, and CE ac-
tivities; and unexpected or unintended outcomes of
CE. The framework was then periodically amended to
incorporate emerging sub-themes such as the contrasting
goals of different key actors involved in CE. All coded data
were exported into charts in MS Word 2007 (Microsoft,
Washington, USA) to explore the diversity of viewpoints
by categories of actors and trial sites and emerging pat-
terns. For observational data, detailed notes were trans-
formed into summaries based in part on the interview
themes. Survey data were double entered in Visual FoxPro
v9 (Microsoft, Washington, USA) and later exported to
STATA v11 (StataCorp, Texas, USA) to conduct simple
frequencies, Pearson’s chi-square test of association
(where necessary) and cross-tabulations of key informa-
tion by trial site (based on qualitative data indicating its
importance).
Ethical considerations
Ethical approval for the trial itself was obtained from in-
stitutional review committees and the National/KEMRI
Ethical Review Committee before the trial began (ProtocolTable 3 Summary of community engagement activities1
Period Activity Who involved
Month 1 Consultation and sensitisation of Kilifi
District stakeholders
1. MoH structure: Di
Kilifi District Hosp
2. Provincial adminis
working in Kilifi D
Months 2
to 6
Community entry and sensitisation of
stakeholders in sites A, B and C
respectively




3. Others: primary sc
Months 8
to 13
Identification and recruitment of 5 to




Identification and recruitment of 6 to




Follow-up of research participants Fieldworkers
Continuous feedback to and from
community
Fieldworkers and oth
Feedback of results Involves all of the ab
1Source: Angwenyi V, Kamuya D, Mwachiro D, Marsh V, Njuguna P, Molyneux S: Wo
practical and ethical experiences and implications. Dev World Bioeth 2013, 13:38Number: SSC1445). Approval for this mixed methodology
sub-study was obtained later and separately (Protocol
Number: SSC 1541). All sub-study data were anonymized,
and stored in password protected computers and in lock-
able cabinets with personal identifiers removed. Consent
was obtained from interviewees. Feedback meetings among
the social science team, and with key members of the trial
team, were held regularly to ensure that emerging issues
were shared and acted upon by the trial team.
Results
Following an overview of the trial CE strategy and of the
variations by facility, or site, we describe in turn: the
views of the early activities leading to trial recruitment
(community consultation, entry and sensitisation); the
levels of trial understanding among participants’ parents
(one key aim of early CE activities); and continuous en-
gagement and feedback of findings. As observed else-
where, much of the CE focussed on the early activities,
which included strengths and challenges that we discuss
related to: involvement of existing community gate-
keepers and leaders; aligning and embedding activities in
existing activities and structures; and the terms used in
information sheets and consent forms.
CE strategy and variations by site
The formal and basic CE activities which took place over
the trial’s first few years are summarised in Table 3.
Through observations and interviews, we noted particular
emphasis at the outset on consultation and planning with
key stakeholders, including the Provincial Administration
(district officers, chiefs and village elders) and the MoHstrict Medical Officer of Health and District Health Management Team at
ital. All health facility in-charges working in Kilifi District
tration structures: District Commissioner, Senior District Officer, all chiefs
istrict
spensary health committees, dispensary staff (facility in-charges, nurses,
ers, community health extension workers), and community health
on: District officers, local (assistant) chiefs and village elders




ove, for example, preliminary study results disseminated
rking with community health workers as ‘volunteers’ in a vaccine trial:
–47.
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CHWs.
Sensitisation and recruitment activities were then im-
plemented in site A, followed by site B and then site C.
In each site, initial consultations with community leaders
were followed by sensitisation meetings for the general
community, but particularly targeting families with eli-
gible children. Meetings were organised by trial staff in
liaison with community leaders, with key messages de-
veloped by the CAST group. Sensitisation activities were
followed by consent and recruitment activities, and over
the course of the trial, field staff and community leaders
were generally considered by the research team as the
channel for community members to voice any concerns.
As is often the case [5], consent processes for this trial
were embedded within the wider CE activities, but con-
sidered as a separate, more specific and individualised
activity. From the outset, feeding back of individual and
research findings at the end of the trial was considered
essential [15].
Although the overall community sensitisation plan for
key stakeholders (chiefs, village elders, CHWs, health fa-
cility staff and health committees) was the same across
sites, some changes were reported and observed over
time. These changes are summarised in Table 4, but two
illustrative examples are described here. Firstly, there were
changes in the extent of involvement of key community
stakeholders, and the amount of community based infor-
mation sharing and sensitisation. For instance, CHWs
were increasingly involved in giving general information
about the trial to potential participants in the community,
but over time there was generally less community based
information sharing; that is there were fewer household
visits and fewer large public meetings in sites B, and espe-
cially C, than in A.
Trial staff attributed these changes to less need for
large scale community based information over time be-
cause of fewer concerns about the purpose, amount and
use of blood taken, and about trial safety. In site A, these
concerns reportedly led to numerous questions fromTable 4 Summary of changes in community engagement by s
Study site Site A
Prior exposure to KEMRI Less
Perceived ease on recruitment/amount of CE activities Harder/more CE
CE and consent process changes (across sites) • Provider of initial tr
• Provider of detailed
• Disclosure setting o
• Consent setting: m
• Time consent is sou
consultation and di
• Administration of c
CE, community engagement; CHW, community health worker.community members, and apparently fuelled rumours
about KWTRP. Commonly reported rumours were
KWTRP being ‘devil worshippers’ and children being
likely to die on receipt of the vaccine. Such rumours not
surprisingly led to further questions and concerns, and
to low recruitment rates, and to more community meet-
ings than had initially been planned, to supplement
household follow-up visits:
…there should be barazas [public meetings], so that
those who are not involved they will be able to ask
and get answers to their questions. But this [research]
didn’t come that way. Initially after they informed
leaders, village elders and CHWs, they went straight to
meet people who had [eligible] children. So this is what
brought problems they forgot that there are those others
whom we call ‘wajuaji’ [referring to knowledgeable
people/influential figures - no direct translation], who
were left out … [yet] they are listened to in the
community (IDI01_male, community leader, site A).
… If they could have started with meetings [in a
central place] and then gone around to people’s homes
then they would have succeeded. It’s like climbing a
tree from the top to the bottom, when everybody knows
you should start from the bottom and climb up’
(IDI07_male, parent, non-consenter, site A).
Although more public meetings or barazas were orga-
nised to inform a wide range of community members,
challenges with such meetings is the absence of many in-
fluential figures, especially fathers of young children, and
inability to cover detailed information and have one-to-
one discussions. Thus, home visits remained a key sensi-
tisation strategy in all three sites:
… a lot of them [women] have to seek consent from
their husbands, and therefore if the husband says
[in a household visit] ‘oh yeah you go listen and join
the study’, then they are more likely to … [since] theyite and over time
Site B Site C
Less More
Easier/moderate CE Easier/less CE
ial information: more by CHWs but less detailed
study information: more by experienced facilitators and clinicians
f initial trial information: more in community than in homes
ore in facilities than in homes
ght: closer to time of recruitment; less time for intra and inter family
scussion
onsent: less access in advance to consent forms with ‘scary wording’
Table 5 Sources of information prior to and post joining







Perceptions on who to
approach before a trial
starts in future similar
studies n (%)
FWs at home 138 (69.6) 120 (74.5) N/A
FWs elsewhere 49 (27.1) 24 (50.0) N/A
Dr./KEMRI staff
(facility)
138 (71.3) 78 (48.7) N/A
Dr./KEMRI staff
(home/village)
87 (45.8) 25 (34.7) N/A
Friends/
neighbours
93 (46.7) 30 (35.3) 132 (72.9)
Health facility
staff
49 (24.8) 24 (45.3) 171 (96.1)
CHWs 103 (52.6) 24 (23.3) 169 (90.9)
Village elders 104 (52.8) 22 (23.9) 194 (99.0)
Chiefs
(sub-chiefs)
97 (49.0) 26 (30.2) 196 (99.5)
Religious leaders 19 (9.6) 8 (40.0) 140 (76.5)
Traditional
healers
4 (2.1) 3 (33.3) 53 (29.1)
Parents with
eligible children
N/A N/A 184 (96.3)
Others (specify) 31 (19.0) 9 (25.0) 41 (24.1)
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speak to them [women] in a baraza [public meeting]
and then they go explain to their husbands, the
response is not so good (IDI04_female, trial staff ).
A second example of a change over time is regarding
who administers consent and where. Initially, consent in-
formation was provided in potential participants’ homes
by FWs employed from the local community. In house-
hold interactions and CAST discussions, it was noted
however that newly trained FWs could not always address
emerging and technical questions about the trial, and that
parents might feel pressurised to consent when visited in
their homes. FWs’ roles were therefore limited to assisting
in general information in the community. Parents inter-
ested in participating were invited to visit health facilities
for more detailed study information provided by experi-
enced community facilitators and trial clinicians. Group
information was followed by individual consent processes
led by clinicians who speak the local dialect.
Community consultation, entry and sensitisation
Overall, trial staff, community leaders and participating
households reported that CE activities and interactions
helped clear pre-existing concerns and misconceptions
about KEMRI’s work; raised awareness; built trust; and
increased the visibility of KEMRI staff initially seen as
‘outsiders’.
It was very, very hard in fact at the initial stages …
KEMRI was being associated with devils, and that was
the story in the community then, but I commend the
entry point. Before they started this whole project there
was very, very good interaction between you people
[KEMRI staff], and how you entered these
communities through DHCs [dispensary health
committees], chiefs, and barazas [public meetings].
It helped a lot. I think that’s why after a short time
community members accepted because now I don’t
hear any problems of maybe community members
complaining … (Group interview2_male, health
facility staff, site B).
… the understanding of KEMRI here is much, much
more positive than it was … because of the approach
that they [KEMRI] used. The concern of the local
people particularly about this research was mistrust,
mistrust of KEMRI as a body [institution] … it
[the approach used] has helped give a positive image
of KEMRI we can really trust (IDI02_male,
community leader, site A).
The overall importance of the initial CE, and the strat-
egies used, was supported by participating households intheir responses to the survey. Over 95% of survey re-
spondents recommended that future similar trials should
inform each of chiefs, village elders, parents of eligible
children and health facility staff in advance of trials, and
91% mentioned CHWs (Table 5).
Involvement of existing community gatekeepers and
leaders
Most staff, parents and community leaders interviewed
reported that it was essential to incorporate pre-existing
decision-making structures such as district officers,
chiefs and elders into CE strategies. These individuals re-
portedly helped build trusting relationships between re-
searchers and community members because they are
well recognised, trusted and respected:
You know when something new is starting, it always
has problems. Like the leaders; they were ring leaders
explaining that this [research] had no problems.
Communities really trust their area leaders rather
than just anybody coming from nowhere to go and
explain to them … (FGD02_male fieldworker, site C;
researchers’ emphasis).
Some community leaders reportedly went ‘an extra
mile’ to support the trial and minimise concerns through
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ings, and even enrolling their own children:
… someone like the assistant chief … recruited his
children in the study and that was like a good mirror
to the community. So he would even say ‘I have
enrolled my children in the study and since I joined
there have been no effects. So you should not spread
propaganda that KEMRI is bad, no!’ So this to me and
even to the community was something good
(FGD02_male, fieldworker, site C).
We called all pastors here, CBO [Community
Based Organisation] leaders … and then we
brought in representatives from health facilities
and we had a meeting here [at the office].
So ours basically was to try and seek how the
combined efforts can help us inform the general
community and educate them to know that KEMRI
does this and this (IDI02_male, community leader,
site A).
There were also some challenges with involving com-
munity gatekeepers and leaders. There were numerous
requests for assistance, for example for lifts from KEMRI
vehicles, for allowances, for construction or decoration
of offices, and for bicycles or future employment. More-
over, during recruitment difficulties, some chiefs and
leaders apparently attempted to ‘exert pressure’ on
people to enrol, through demanding from elders why re-
cruitment challenges are being faced (site A), threaten-
ing to withdraw people from a local food for work
development project (site A), and saying they would ar-
rest rumour mongers (site C). Some of these incidents
clearly presented potential threats to the voluntary na-
ture of research participation and had to be addressed
by the trial team through subsequent information giv-
ing sessions.
… village elders tended to be coercive sometimes …
you could go with them [to homes] and you know
that … [research] participation is voluntary. But
then for a village elder, because he wants the
[research] agenda fulfilled then he says, ‘we want
everybody who has an eligible child to join the
study, or else we will make sure you are removed
even from other government projects that are
brought here’. So in such a place you [fieldworker]
have to come back again and try to explain that
this [research] is not a must, it’s voluntary
(FGD01_male, fieldworker, site A).
In some cases, unexpected and unintended initiatives by
gatekeepers were appreciated by community members,illustrating the complex potential role that such actors can
play in information sharing and recruitment:
… we went to the meeting and the assistant chief said
he doesn’t want to hear any rumours from anybody.
He said he was an assistant chief and he had a child
who was in the KEMRI study. He told people if they
won’t enrol in the study they should just keep quiet
and anybody who will be heard spreading rumours
will be arrested … After the assistant chief called the
meeting, rumours stopped and for us who had already
joined, we felt a bit better because rumours had
stopped (IDI11_female parent, late consenter, site C).
Parents recognised the key role of community leaders
in assisting with information giving and addressing com-
munity concerns. However, for decisions on whether or
not to involve their child in the trial, those most often
mentioned as being consulted by parents were spouses and
close family members (55.0%; n = 110). Almost all parents
(91.5%, n = 183) reported the final decision to enrol was
theirs and voluntary.
Aligning and embedding CE in existing structures and
activities
Consultations with community gatekeepers were de-
scribed by researchers as helping to identify additional
ways of communicating about the research. For instance,
MoH officials strongly promoted from the outset using
existing structures like CHWs rather than creating paral-
lel community representative groups such as community
advisory boards, or KEMRI community representatives;
see also, [10]. Aligning CE activities for the trial with
those already planned by key community gatekeepers
was considered by most interviewees as an appropriate
approach to reach out to as many people as possible
with study information (Table 6).
… there were those [meetings] which community
[leaders] themselves had already organised according
to their calendar. We could get a bigger crowd [and]
then ask for a slot [within that larger meeting] to
sensitise the community about the study. For the
meetings which we organised [ourselves], initially they
were a bit difficult. Sometimes you organise for a
meeting and when we go for that meeting, very few
people turn up (IDI05_ male, trial staff ).
However, contrasting advice from different community
gatekeepers presented the trial team with dilemmas.
Thus for example, some community leaders suggested
that traditional healers should receive targeted sensitisa-
tion, whereas facility staff and MoH managers were ad-
amant that traditional healers should not be included
Table 6 Key actors (and those suggested) for community engagement activities (observation and interviews data)




Chiefs and Village elders)
1. Consultation and entry. For example: 1. Conducted additional sensitisation activities in the absence
of KEMRI staff and warn people to avoid politicizing the
research process in community barazas (public meetings)
1. Contribute to success of the trial, defined primarily as
achievement of sample size and general smooth running
• Seek support and permission to carry out
the trial
2. Asked participants to speak about their experiences in public
meetings
2. Community health benefits, for example, construction/
expansion of HF and improved quality of care
(ambulatory services, skilled staff, and so on)
• Gather opinions on who should be
targeted with study information and
identify other opinion leaders
3. Intervened during low recruitment to emphasize others to
join the trial, including through demanding from leaders
why recruitment challenges are being faced (site A), and
threatening to withdraw people from food for work project
(site A), and to arrest rumour mongers (site C).
3. Personal or professional gains, for example, lifts from
KEMRI vehicles, allowances when engaged in activities,
increased status/recognition through affiliations with
KEMRI/staff, assistance in constructing offices, and being
seen as successful, that is, through introducing a (quasi)
government project
2. Sensitisation and mobilisation. For
example:
4. Made many requests for personal or professional gains, for
self, or others.
• Create awareness of KEMRI and
understanding of trial activities in their
jurisdiction
• Assist with meetings for other opinion
leaders and community members through
barazas (public meetings)
3. On-going communication. For example:
• Be aware of trial and procedures if
contacted by concerned community
members
• Forward community issues to study team
where necessary
Community organisations/
forums (for example, a
local district stakeholders’
forum)
1. Sensitisation and mobilisation. For
example:
1. Assisted in giving simplified information at large meetings.
Assisted in clearing community concerns about KEMRI’s work
1. Gains to the organisations that they are part of - for
example membership fee to the organisation
• Create awareness of KEMRI and
understanding of trial activities
2. Made some requests to KEMRI for the organisations that
they represent
2. Protection of the community against risks and concerns
• Encourage interested community members






1. Benefit community and build trust
through employing members using
transparent mechanisms
1. Communicating constantly with community members
through their roles and in their personal lives as they live in
the community, including through handling numerous
questions
1. Meet recruitment targets to maintain jobs
2. FWs conduct their formal study roles which
include sensitisation and mobilisation,
constant feedback to study team, and
feedback of individual and study findings
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In this case, a compromise was reached: there were ef-
forts to include healers in wider community meetings, but
they were excluded as a specific CE channel. Another ex-
ample was that a location-level stakeholder group wanted
KEMRI to be a member and attend their meetings. How-
ever, membership required payment, which raised con-
cerns that this would potentially lead to payment requests
from numerous other groups, or might be interpreted as
‘buying’ local support. In this case, after extensive consult-
ation, KWTRP (as opposed to the trial team specifically)
did join and paid the nominal membership fee; none of
the anticipated problems have yet been reported.
In terms of involving CHWs, we have discussed the
complexities of this in detail in another paper [10].
Briefly, CHWs were initially engaged as an important
network to be informed about the trial. However over
time, and in response to community advice, they became
involved in trial information sharing and identifying po-
tential participants; thereby taking on roles that over-
lapped with those of employed FWs. While CHWs’
involvement was generally perceived as positive and ap-
preciated, there were challenges in their relations with
FWs and with other community members, partly related
to different levels of remuneration.
Concerns associated with approved study information
sheets
An issue recognised and discussed often in public meet-
ings and in homes particularly at the outset of the study,
and linked to pre-existing concerns and rumours about
KEMRI being ‘devil worshipers’, was some of the local
wording in information sheets and consent forms for
compensation and randomisation. Particularly problem-
atic was the translation of ‘randomisation’ into ‘pata
potea’; (which translates to win or lose) a local dice game,
with animals drawn on the dice instead of numbers. Ra-
ther than being interpreted as being assigned to the ex-
perimental vaccine (win) or control (lose), the explanation
was understood to mean the possibility of losing a child.
This also fed into perceptions that the experimental vac-
cine was already known to work.
Related to concerns about pata potea, some partici-
pants also interpreted compensation for adverse events
to imply a high possibility of death. A FW summarises
the concerns in the community:
… there was a form [informed consent] which was
written that if the child dies you will be given ‘fidia’
[compensation] … when my wife and I heard that
there is ‘fidia’ [compensation], she said I don’t want
(laughter) … if I give them my child and the child dies,
then they give money, that will not bring my child
back. We had to explain to her until she understood.And in fact, some refused at that stage when they
heard of KEMRI giving ‘fidia’ [compensation], they
said ‘we don’t want our children in it. You want to
take our child and give that child to the devils’ …’
(FGD04_male, fieldworker, site A).
The confidentiality clause in the informed consent form
(ICF) also appeared to cause apprehension amongst some
participants; increasing rumours and concerns about
why KWTRP activities should be shrouded in secrecy.
They wondered why confidentiality was important when
most people in their community knew of their research
participation.
There is this part of confidentiality, the locking of
documents in cupboards; sometimes when you explain
that to your participants they wonder about it … it’s
like something will happen in the future which will
surprise them … [that] information that is kept in
cupboards and in the computers, why does it have to
be secret? (FGD05_male, fieldworker, site B).
Levels of trial understanding among participants’ parents
The household survey included questions on under-
standing of the trial, and on processes and voluntariness
in decision-making. It should be reiterated however that
these questions were asked one year after initial recruit-
ment and informed consent (Table 7).
Survey results indicate fairly low levels of understanding
one year post recruitment. For instance although almost
all parents were aware that their child was receiving a vac-
cine (96%, n = 192), only 31% (n = 62) reported that the
main purpose of the activity was to learn about the vac-
cine’s potential to prevent malaria; 14.5% (n = 29) of par-
ents reported that not all study children received a
malaria vaccine and 15% (n = 30) reported that their chil-
dren could still get malaria. There seemed to be less un-
derstanding of the purpose of the trial where there
was least amount of CE, and where recruitment was
considered by trial staff to be ‘easiest’. That is, the propor-
tion of parents from each site who reported prevention of
malaria as the main purpose of the activities was 40.3%
(n = 27/67) in site A, 36.4% (n = 12/33) from site B,
and 23.0% (n = 23/100) from site C. The differences were
statistically significant between sites A and C [x2 (1), =
5.72, P < 0.017].
After one year of experience of the trial, 93% (n = 186)
of parents reported that they were content with their de-
cision to join the trial, and only 1% (n = 2) said that they
would not consider joining another future similar trial.
This suggests an overwhelming proportion of participat-
ing parents did not later regret the decisions they made
about their child’s enrolment. Parents’ reasons for their
positive perceptions of the trial were: the rumours and
Angwenyi et al. Trials 2014, 15:65 Page 12 of 16
http://www.trialsjournal.com/content/15/1/65concerns circulating early on in the trial had been shown
to be untrue; trial participants’ access to free and good
quality health care; the perception that the vaccine was
successful; and the caring attitude of the trial staff (see
also Table 7).
Continuous engagement and feedback of findings
There were some concerns raised by community gate-
keepers and staff that CE activities began to reduce over
time, once trial numbers had been reached:
I think there is a gap there because the trend is, once
you give this information and maybe … you recruitTable 7 Consent processes and understanding of the trial (Ho
Main purpose of the trial
Provide treatment/help to participating children
Learn about potential for preventing malaria
DK
Other activities
Missing/data not clear to code


















Most important reasons for enrolling in trial (top five)
Access to free treatment
Access to better and quality services
Vaccine beneficial
Detailed explanation of the study
Previous experience/interaction with KEMRI
aHere most people reported they would first want to hear more about what the trial w
DK; do not know.numbers [required], then the forum for holding
barazas [public meetings] and continuing to give
information comes to an end, because we’ve got the
target (IDI05_male, trial staff ).
This gap was discussed with the trial team, and ad-
dressed through ensuring that trial or CLG staff regu-
larly attended community leaders’ meetings. In addition,
and as planned from the outset, the feedback of prelimin-
ary results to the study communities in November 2011
and October 2012 became additional opportunities to en-
gage with participants and community leaders. In each
site, feedback meetings were organised for participatingusehold survey)
Site A Site B Site C Total
n = 67 (%) n = 33 (%) n = 100 (%) n = 200 (%)
32 (47.8) 18 (54.5) 71 (71.0) 121 (60.5)
27 (40.3) 12 (36.4) 23 (23.0) 62 (31.0)
3 (4.5) 1 (3.0) 3 (3.0) 7 (3.5)
2 (3.0) 0 2 (2.0) 4 (2.0)
3(4.5) 2 (6.1) 1 (1.0) 6 (3.0)
38 (56.7) 19 (57.6) 63 (63.0) 120 (60.0)
12 (17.9) 6 (18.2) 11 (11.0) 29 (14.5)
17 (25.4) 8 (24.2) 24 (24.0) 49 (24.5)
0 0 2 (2.0) 2 (1.0)
10 (14.9) 5 (15.2) 15 (15.0) 30 (15.0)
32 (47.8) 17 (51.5) 56 (56.0) 105 (52.5)
25 (37.3) 11 (33.3) 28 (28.0) 64 (32.0)
0 (0) 0 1 (1.0) 1 (0.5)
45 (67.2) 20 (60.6) 80 (80.0) 145 (72.5)
2 (3.0) 0 0 2 (1.0)
20 (29.9) 13 (39.4) 20 (20.0) 53 (26.5)
61 (91.0) 31 (93.9) 94 (94.0) 186 (93.0)
4 (6.0) 0 2 (2.0) 6 (3.0)
2 (3.0) 2 (6.1) 4 (4.0) 8 (4.0)
18 (26.9) 10 (30.3) 35 (35.0) 63 (31.5)
9 (13.4) 6 (18.2) 25 (25.0) 40 (20.0)
12 (17.9) 5 (15.2) 13 (13.0) 30 (15.0)
5 (7.5) 3 (9.1) 7 (7.0) 15 (7.5)
3 (4.5) 4 (12.1) 6 (6.0) 13 (6.5)
ould involve at the point of information giving before making their decision.
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over two days, immediately following the official global
launch of results [21]. Thereafter FWs visited each partici-
pating household with official letters summarising key
meeting information.
Feedback meetings were well attended with over 66%
(n = 598/904) of participating households represented in
the two-day meetings in 2011. Meetings provided an op-
portunity to reiterate the study aims and importance of
the trial, and to thank participants’ parents for their par-
ticipation in the trial. The preliminary trial results com-
municated see also [21], highlighted the trial vaccine
continued to be safe and protect against clinical malaria
by 55.8% among children aged 5 to 17 months at enrol-
ment, who had received three doses of the vaccine and
who were followed up for 12 months. These findings ap-
peared to further alleviate concerns about the trial and
encourage participating parents to keep their children in
the trial:
… mothers [parents] were very happy because at least
they saw that their efforts of coming here [at the
health facility] for the vaccine was not wasted and so
there was something truly going on. Therefore when
they got these results they knew that this study was
real. Another thing they were happy about was the
way they were being followed up by those
[fieldworkers] who oversee the project at their village.
It was a clear indication that they [parents] were a
very important link in the study (FGD06_male,
fieldworker, site A).
Discussion
The potential importance of CE, but also the complexity
and possibility of unexpected negative outcomes, has led
to calls for greater documentation of CE processes in
practice. In this paper, we have shared experiences of
formal CE for a paediatric randomized controlled mal-
aria vaccine trial conducted in three different sites in
one geographical area of Kilifi County in Kenya. Having
this study conducted alongside and feeding into on-
going CE for the trial, and by social scientists (VA, DK,
VM, SM) employed by the wider KWTRP, could have re-
duced our independence and critical analysis. However,
we feel we benefited from both an insider status (the wider
KWTRP) and outsider status (from the trial outcome); in-
cluding building trust with the trial team, capturing the
shifting day-to-day trial experiences, and ensuring that
concerns we identified were discussed and - where appro-
priate - acted upon.
Overall, the CE approach and activities were consid-
ered appropriate by the various stakeholders interviewed
(trial researchers, FWs, community leaders and parents),
with activities apparently assisting in reducing concernsand misconceptions among potential participants, and
increasing visibility, awareness of and trust in trial staff.
However, several findings warrant further discussion, in-
cluding if and how rumours and concerns about the trial
and KWTRP were fuelled by information sheets and
consent forms, the apparently low levels of trial under-
standing despite the amount of CE, and what emerge as
the contrasting and sometimes conflicting goals of dif-
ferent actors involved in CE.
Consent information feeding into rumours and concerns
in local communities
One goal of CE among researchers was to build levels of
trust so that potential participants would consider their
child’s participation; a more specific goal was to ensure
that participants’ parents were adequately informed about
the study, and able to make their own decision about par-
ticipation without undue influence by others.
In this trial we document very similar rumours and
concerns to those we have reported elsewhere on the
Kenyan Coast [13-15] and that have been identified
across Africa [25-27]. As many of these papers argue,
these rumours should be taken seriously as a real con-
cern, and as an expression of uncertainty, tension and
ethical comment in settings with long histories of pov-
erty, inequity and invasion. The strength for communi-
ties of rumours lies in the importance but difficulty of
confronting them: simply re-stating the scientific facts or
supplementing explanations with demonstrations is in-
adequate [13]. The CE activities for the trial discussed in
this paper were therefore only partially about promoting
understanding of study details; also crucial was reducing
suspicion and fears, exhibiting behaviours such as truth-
fulness, concern, and fairness, and ultimately building
trust.
We have shown how information in a consent form
(and broader CE and consent processes) can not only
fail to clear anxieties and fears, but even fuel them. In-
formation can be interpreted very differently by trial
staff, reviewers of consent forms, and community mem-
bers: messages designed to clarify issues and rights, even
when designed following carefully developed local pro-
cesses [28], can be drawn upon by community members
to raise concerns and challenge researchers in powerful
ways. For example in this study, anxieties raised with in-
formation on risk and confidentiality in information
sheets led to shifts in the foci and tone of CE activities.
Although rewording of forms may have reduced some of
the concerns, the specific words triggered and enabled
discussions about pre-existing tensions and worries that
required positive reaction and engagement by the re-
search team to build relationships and trust [13,14].
These findings also illustrate the very different percep-
tions there are of (signed) consent forms and processes
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in which they originate [29], and how they potentially
feed into very different concepts of study-related risk
that different actors might bring to an engagement activ-
ity [30].
Community engagement and levels of understanding of
the trial
Having noted that CE activities were as much about re-
lationship building as information sharing, clearly the
two are inter-related, and a key aim of CE here as else-
where is to support consent processes. We recorded low
levels of understanding of key trial information one year
after enrolment, but significantly higher levels of under-
standing in the first site where there was greatest CE.
While there might be some temptation to attribute
greater understanding to higher levels or different forms
of CE, these differences could have resulted from other
factors such as amount of previous exposure to research
(site C had greater exposure potentially leading to less
confusion with other studies).
These data on understanding should be interpreted
with caution. Firstly, ‘understanding’ is notoriously diffi-
cult to define and measure, particularly through a relatively
simple survey tool conducted long after the consenting
process [31]. A particular challenge in resource poor set-
tings is the possible crowding out of research information
over time by more prominent interests and concerns
among participants or their carers, such as access to study
benefits including much needed free medical care
[6,12,32]; certainly a strong possibility in this trial. Sec-
ondly, and in part because of the challenges of measuring
understanding and the debates about what to do in the
case of apparent ‘inadequate’ levels of understanding
among potential participants, some authors have argued
that the key concern in consent processes should be that
people are empowered to make decisions that are appro-
priate for themselves about participation [31]; decisions
that they do not go on to later regret once they experience
what the study actually involves (as opposed to hearing
about it before it begins). Our data suggested that partici-
pants’ parents generally did not regret participating one
year into the trial, although it is important that this does
not equate to their having made an informed decision
about participation at the outset, or about staying in the
trial. Some parents who did not consent apparently later
regretted that decision (anxieties about risks such as chil-
dren dying or health deteriorating subsided, and partici-
pating children enjoyed study benefits), but it is difficult
to imagine how this situation might have been prevented
beyond the activities described above.
The apparently low levels of understanding one year
into the trial remains a concern. Although this is far from
unique to this trial or setting [5], it illustrates the verydifferent priorities and concerns different actors bring to a
research encounter, and the importance of continuing CE
over time. For this trial, feedback activities provided an
opportunity for key messages about the trial to be reiter-
ated and discussed. This appeared to be appreciated and
to improve understanding, but this understanding needs
to be documented more quantitatively.
Complex and contrasting goals for CE among key actors
Over the course of the observations and interviews it be-
came clear that the trial team and others involved with
CE activities had different motivations or goals for in-
volvement in the trial. These goals were not articulated
but revealed through actors’ additional and un-anticipated
activities (see Table 6 for an illustrative extract), which re-
veal the very different realities and interests brought to CE
activities and interactions. CE can therefore be understood
as interface activities; where different interests, relation-
ships, modes of rationality and power intersect, and some-
times conflict [33]. CE activities can therefore take on a
life of their own; transforming planned interventions into
socially constructed and (re) negotiated processes.
The translation and constant reshaping of activities in-
volves diverse and multi-layered practices of power. In
some cases the most commonly recognised form of
power - authoritative power - can be used to dominate
and prevent others from expressing their opinions and
actions. For example, we reported incidences of chiefs
and elders trying to exercise their authoritative power
over community members who were not keen for their
children to participate. These incidents have worrying
implications for voluntariness in consent processes,
protected against to some extent by final information
sharing and consent being conducted individually by
trained clinical staff not embedded in study commu-
nities. In other cases, those considered to be relatively
powerless exert their own influence on activities and in-
teractions through exercising their discretionary power.
For example, FWs returned to households to reassure
participants where they felt that leaders had been in-
appropriately persuasive, or community members spread
rumours which could be challenging for researchers to re-
spond to.
Beyond the functioning of the trial itself, goals of actors,
and how they are responded to, can also have wider impli-
cations. Thus for example, and as we have described else-
where [10], CHWs’ health care roles in the community
were under-resourced at the time of this trial, and there-
fore depended largely on their intrinsic motivation such as
their ability to gain social recognition, knowledge and to
make a social contribution through performing their roles.
These intrinsic motivations may have been crowded-out
by the extrinsic motivations introduced by the trial as part
of the CE activities.
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The everyday engagement activities of all actors involved
in this trial, including the use of authoritative and discre-
tionary power, had the potential to both assist with and
undermine the trial team members’ goals for CE. Of
interest is that the trial teams’ goals for engagement were
relatively clear and openly shared with all from the outset.
Other actors’ hopes and expectations were not openly
sought and discussed, but emerged over the course of en-
gagements, in some cases in frustrating or worrying ways.
Encouraging open discussion of all actors’ intentions and
goals from the outset takes time, risks raising expectations
that cannot be met, and is complex given the necessarily
constantly shifting nature of who is engaged with over
time and in what way. Counter arguments might be that
some of the unanticipated activities that had the potential
to undermine the trial team members’ intentions for CE
might have been avoided if different interests had been
more fully understood by all from the outset.
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